TUG1 |
↑ |
promotes cell proliferation, inhibits apoptosis, inhibits G0/G1 cell cycle arrest |
sponges miR-9-5p:downregulates POU2F1 expression |
[29, 49–51, 87] |
associated with tumor size, clinical stage and post-operative chemotherapy |
downregulates POU2F1 expression |
correlated with poor prognosis and disease status |
|
an independent prognostic indicator for overall survival |
|
HOTAIR |
↑ |
promotes cell proliferation, invasion and secrection of MMP2 and MMP9 |
— |
[62, 67, 68] |
MALAT1 |
↑ |
promotes cell proliferation and meatastasis |
activates PI3K/AKT signaling pathway; |
[53–56] |
|
involvement of RhoA/ROCK Pathway |
|
MALAT1/MIR376A/TGFA axis |
|
regulated by Myc-6 |
H19 |
↑ |
promotes cell proliferation, inhibites apoptosis |
interacts with miR-141 |
[60, 61] |
induces osteosarcoma development |
involvement of Hedgehog signaling |
HULC |
↑ |
correlated with clinical stage, and distant metastasis, but not in another study |
— |
[78, 79] |
correlated with shorter overall survival |
|
SNHG12 |
↑ |
promotes cell proliferation and migration |
upregulates angiomotin gene expression |
[45] |
MFI2 |
↑ |
promotes cell proliferation, suppresses apoptosis |
upregulates FOXP4 expression |
[46] |
PACER |
↑ |
promotes cell proliferation and metastasis |
activates COX-2 gene in a NFκB-dependent way |
[47] |
BCAR4 |
↑ |
correlated with large tumor size, advanced Enneking stage, lung metastasis, |
activates GLI2-dependent gene transcription |
[80] |
and poor prognosis |
|
HNF1A-AS1 |
↑ |
associated with clinical stage, distant metastasis, and poor overall survival |
activates Wnt/β-catenin signaling pathway |
[44] |
BANCR |
↑ |
associated with large tumor size, distant metastasis, and advanced clinical stage |
— |
[27, 86, 110] |
an independent predictor of poor survival |
|
UCA1 |
↑ |
correlated with large tumor size, high tumor grade, distant metastasis, |
— |
[81] |
and advanced clinical stage |
|
an independent unfavorable prognostic factor |
|
91H |
↑ |
correlated with advanced clinical stage, chemotherapy after surgery, |
— |
[88] |
and tumor size >5 cm |
|
an independent prognostic factor for overall survival |
|
ODRUL |
↑ |
contributes to doxorubicin resistance |
induces multidrug resistance-related ABCB1expression |
[77] |
HOTTIP |
↑ |
correlated with advanced clinical stage, distant metastasis and poor prognosis |
interacts with WDR5/MLL complex |
[83, 108, 109] |
increases cisplatin resistance |
activates Wnt/β-catenin signaling pathway |
FOXC2-AS1 |
↑ |
influences tumor angiogenesis and metastasis |
upregulates ABCB1, HIF1A and FOXC2 expression |
[20] |
associated with poor chemoresponse and longer survival time |
|
contributes to doxorubicin resistance |
|
LINC00161 |
↑ |
increases cisplatin-induced apoptosis |
sponges endogenous miR-645 |
[107] |
reverses cisplatin resistance |
upregulates IFIT2
|
ZEB1-AS1 |
↑ |
promotes cell proliferation and migration |
binds and recruits p300 to the ZEB1 promoter region, |
[48] |
correlated with large tumor size, progressed Enneking stage, tumor metastasis, |
activates ZEB1 transcription |
worse recurrence-free and overall survival |
|
loc285194 |
↓ |
promotes cell growth |
induced by p53,interact with miR-211 |
[70, 71] |
MEG3 |
↓ |
associated with poor overall survival |
positively regulates p53 expression |
[84, 85] |
TUSC7 |
↓ |
promotes cell proliferation and increases colony formation in vitro |
— |
[43] |
HIF2PUT |
↓ |
promotes cell proliferation and migration |
positively correlated with HIF-2α expression |
[94] |
decreases the percentage of CD133 expressing cells |
|
impaires the osteosarcoma stem sphere-forming ability of the MG63 cells |
|